Read More

Reported Late Tuesday, AdaptHealth Provides FY23 Guidance And Preliminary Commentary On Q4 2022 Results; Sees FY23 Revenue $3.21B-$3.29B; Adj. EBITDA $690M-$750M; Sees FY22 Revenue To Be Near Midpoint Of Previous Guidance Of $2.95B-$3.01B

AdaptHealth Corp. (NASDAQ:AHCO) ("AdaptHealth" or the "Company"), a national leader in providing patient-centered, healthcare-at-home solutions, including home medical equipment, medical supplies and

AHCO